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ABSTRACT 
Analysis of Anti-Retroviral Procurement for HIV-Affected Countries from Fiscal Years 
2012 to 2014 
 
Dejené Marshall 
8/16/2016 
BACKGROUND:   
In 2015, the World Health Organization expanded eligibility for anti-retroviral 
therapy (ART) to all individuals affected with HIV, regardless of CD4 count. Although, anti-
retroviral drugs (ARVs) are essential to HIV/AIDS treatment and therapy, ARVs may also 
pose a financial burden on low-income countries affected by a high prevalence of HIV. 
Programs funded by global donor organizations such as the President’s Emergency Plan for 
AIDS Relief (PEPFAR) may provide assistance to these HIV-affected populations through 
the procurement of ARVs. The objective of this analysis was to determine total ARV 
expenditures for SCMS participating countries from fiscal years 2012 to 2014 and to 
discuss the implications of generic ARV procurement under the WHO and UNAIDS 
guidelines. 
METHODS:  
 The SCMS Delivery History Dataset was used to determine the number of purchase 
orders for generic and brand name ARVs, as well as calculate the expenditures for overall, 
brand name and generic ARVS for 2012-2014.  
RESULTS:   
From 2012 to 2013, the procurement of overall and generic ARVs increased, 
however, from 2013 to 2014, there was a decrease in generic and overall ARV 
procurement. The number of brand name ARV transactions increased during this three 
year period from 78 in FY 2012, 144 in FY 2013, and 164 in FY 2014 respectively. The anti-
retroviral drug Keletra was the most frequently purchased ARV in FY 2012 and FY 2014. In 
FY 2013, the most frequently purchased ARV was Aluvia. 
DISCUSSION:  
It is recommended that the international public health community continues to 
develop more cost-effective methods of procuring ARVs to resource-limited, HIV-affected 
populations. Although there are barriers to obtaining generic formulations for anti-
retrovirals, there are possible consequences of low uptake of generic ARV procurement. If a 
country is unable to efficiently secure enough ARVs for HIV-affected individuals, it is more 
unlikely that HIV/AIDS will be eliminated in that location within the next several years, 
according to the UNAIDS and WHO recommendations.  
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Chapter I 
INTRODUCTION 
1.1 Background 
In 2015, although 36.7 million people were living with HIV/AIDS globally, only 17 
million of those infected with the virus were able to access and undergo anti-retroviral 
therapy (ART) (UNAIDS, 2016). Two-thirds of those infected resided in Sub-Saharan Africa 
(PEPFAR, 2016). UNAIDS suggests that approximately 26.2 billion US dollars will be 
needed for the HIV/AIDS response in 2020 and approximately 23.9 billion US dollars in 
2030 (2016). 
Several international organizations have implemented programs and initiatives to 
address the HIV epidemic. One of the major unifying goals between these organizations are 
the 90-90-90 targets developed in 2014 by Joint United Nations Programme on HIV/AIDS,  
known as UNAIDS. The 90-90-90 targets include the following: 90% of HIV-positive 
individuals will know their status, 90% of HIV-positive individuals will have sufficient ART 
and 90% of those on ART will have viral suppression (UNAIDS, 2014). UNAIDS suggests 
that meeting the 90-90-90 targets by 2020 will result in the end of the AIDS epidemic by 
2030, while acknowledging this is an ambitious goal (UNAIDS, 2014).  
One year later in 2015, the World Health Organization (WHO) published guidelines 
that recommended universal ART for adults, adolescents and children who are HIV positive 
regardless their CD4 count (WHO, 2015). This guideline dramatically increased the number 
of individuals who may need ART and inspired countries throughout the world to revisit 
their national guidelines to meet these new WHO recommendations.  
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The President’s Emergency Plan for AIDS Relief, known as PEPFAR, is the U.S. 
government initiative to globally combat the HIV/AIDS epidemic (PEPFAR n.d.). In 2008, 
PEPFAR was expanded under the Tom Lantos and Henry J. Hyde United States Global 
Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008, 
which authorized 48 billion US dollars towards this multi-year HIV/AIDS strategy 
(PEPFAR, n.d.). Since the launch of PEPFAR until Fiscal Year (FY) 2013, there has been over 
52 billion US dollars committed to various international HIV/AIDS, tuberculosis and 
malaria programs across 54 countries (PEPFAR, n.d.). PEPFAR 3.0 has allocated 
approximately 5.2 million US dollars to bi-lateral HIV/AIDS programs so far in 2016 alone 
(PEPFAR, 2016). Since PEPFAR funds are appropriated through Congress, there are 
accountability measures that must be taken to ensure the proper allocation of funding. 
The Office of the US Global AIDS Coordinator, also known as OGAC, manages the 
entire PEPFAR program and PEPFAR funding. Additionally, OGAC approves all PEPFAR 
activities and funding that is allocated to a country or region. In order for a country to 
receive assistance, their government must work with OGAC to develop a Partnership 
Framework. Partnership Frameworks detail a 5-year plan between the specific HIV-
affected country, the United States Government, and other partners to eliminate HIV/AIDS 
through coordinated financial contributions and service delivery. Then, the host country 
must develop a Country Operational Plan, which vastly details the use of all sources of U.S. 
appropriated funds for each fiscal year, along with several other quarterly and annual 
reports from each PEPFAR site. OGAC reports this information back to Congress on a 
quarterly basis. 
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The Supply Chain Management System, also known as the SCMS, was established in 
2005 under PEPFAR and United States Agency for International Development (USAID) to 
procure HIV/AIDS supplies to partnering countries (SCMS, n.d.). Since then, over 2.6 billion 
US dollars’ worth of essential commodities have been delivered, particularly for anti-
retroviral drugs (ARVs), which dramatically increased accessibility to many HIV-affected 
countries (SCMS, n.d.). Currently, SCMS provides 70 percent of all ARVs that are funded by 
PEPFAR (SCMS, n.d.). 
 
1.2. Purpose  
WHO and UNAIDS’ ambitious goals to eliminate HIV/AIDS reinforce the importance 
of anti-retroviral treatment (ART) for HIV-affected individuals across the globe. Reaching 
these objectives requires an increase in delivery of anti-retrovirals (ARVs) to a larger 
concentration of people. Consequentially, an increase of international ARV funding and 
procurement to resource-limited settings requires a closer look at the global supply chain 
system to ensure that the expenses are appropriately spent and the outcomes are 
maximized. The purpose of this analysis is to review international ARV expenditures and 
discuss the implications of generic ARV scale-up for countries highly affected by HIV/AIDS. 
The data collected will be useful to guide future policy decisions. 
1.3. Research Questions 
1. What are the total ARV expenditures (overall, generic and brand name) for a sample of 
HIV-affected countries from fiscal years 2012 to 2014?  
2. What are the implications of generic ARV procurement under the recent WHO and 
UNAIDS recommendations? 
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Chapter II 
REVIEW OF THE LITERATURE 
In response to the WHO/UNAIDS recommendations, there will be a two-fold 
increase in ARVs supplied worldwide to ensure that all 25 million HIV-affected individuals 
are on treatment (Jamieson & Kellerman, 2016). An estimated 45.8 billion US dollars in 
facility-level resources are also needed to scale up ART from 2015 to 2020 (Dutta, Barker 
and Kallerakal, 2015). Based on these and other recent findings, it is important to review 
previous studies for more cost-effective methods to scale-up ART worldwide. It has been 
proposed that ARV prices must be reduced in order to ensure universal access to ART 
(Vasan et al., 2006). Additionally, international drug tendering processes should be 
negotiated between the partnering country government and the supplier before the 
implementation phase to avoid delays and unnecessarily purchasing expensive ARVs 
(Steyn et al., 2009).  For example, South Africa escalated ART delivery in January 2005 but 
due to an inconsistent flow of ARVs and incomplete drug tendering negotiations, many HIV-
affected individuals died waiting on the first supply (Steyn et al., 2009).  
A study from the Office of the US Global AIDS Coordinator found that by 2008, 90% 
of the 22 million PEPFAR-sponsored ARV packs procured were generic (Holmes et al., 
2010). Generic ARVs are more cost-effective than brand name ARVs, especially when they 
are procured through a global donor organization such as the Clinton HIV/AIDS Initiative 
(CHAI) or the Global Fund (Waning et al., 2009). Additionally, through these international 
organizations, the quality of the ARVs must meet the standards of the WHO Prequalification 
Programme and the United States Federal Drug Administration (FDA) (Waning et al., 
2009). This aims to ensure that quality is not compromised by the price of the ARV.   
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Chapter III 
METHODS 
The SCMS Delivery History Dataset contains transactional information from the 
distribution of HIV/AIDS supplies to PEPFAR-supported countries. USAID collects, 
manages, and publishes the SCMS procurement data on an almost quarterly basis. The 
SCMS Delivery History Dataset used in this analysis was published on the PEPFAR Data 
Dashboard website in the first quarter of the 2016 fiscal year. This dataset was used to 
calculate the expenditures for overall, brand name and generic ARVS for 2012-2014 and all 
costs are recorded in US dollars. There were 33 total data fields included in the SCMS 
Delivery History Dataset, however, only the following eight data fields were used for this 
analysis: destination country, date of delivery to client, product group, item description, 
line item value, pack price, unit price, and first line designation. It is worth noting that both 
adult and pediatric formulations were considered, but the only product group measured 
was ARV. The raw data collected were associated by calendar year, but for this analysis, the 
delivery dates were grouped by fiscal year. Only the line item value and collective unit 
prices were included in the dataset and in some cases, the line item contained more than 
four drugs at a time. Therefore for this analysis, the aggregate totals were calculated in 
Microsoft Excel. Lastly, there were 21 PEPFAR-supported countries that provided 
expenditure information for the SCMS for 2012, and 19 countries in both 2013 and 2014.  
The dataset was cleaned by removing entries that contained duplicates, blanks, null and 
zeros. Microsoft Excel was used to generate PivotTables and charts. Since the data were 
collected from a procurement system and not individuals, Institutional Review Board 
approval was not a requirement. 
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Chapter IV 
RESULTS 
Table 1: Total Generic ARV Expenditures 
from High Burden Countries in FY 2012 
Country ARV Expenditures 
Angola $6,806.40 
Burundi $167,493.51 
Cameroon $6,297,229.33 
Congo, DRC $454,474.97 
Côte d'Ivoire $10,284,116.10 
Dominican Republic $50,787.80 
Guyana $159,026.12 
Haiti $5,912,640.20 
Malawi $5,745,000.00 
Mozambique $17,103,688.22 
Nigeria $41,698,164.61 
Rwanda $6,435,373.72 
South Africa $1,029,267.29 
South Sudan $217,128.46 
Tanzania $17,449,741.06 
Uganda $23,288,284.69 
Vietnam $8,055,755.10 
Zambia $24,057,471.54 
Zimbabwe $18,162,235.57 
Total $186,574,684.69 
 
 
 
 
 
 
 
 
 
 
Table 2: Total Generic ARV Expenditures 
from High Burden Countries in FY 2013 
Country ARV Expenditures 
Burundi $236,728.03 
Cameroon $5,451,156.16 
Congo, DRC $1,036,139.04 
Côte d'Ivoire $11,784,474.95 
Dominican Republic $622,758.46 
Ethiopia $14,975.66 
Ghana $2,865,796.85 
Guyana $194,319.26 
Haiti $2,481,226.20 
Mozambique $45,068,284.16 
Namibia $1,091,981.73 
Nigeria $38,506,387.29 
Rwanda $10,709,618.45 
South Africa $983,092.93 
South Sudan $117,420.34 
Tanzania $27,355,756.54 
Uganda $14,006,450.26 
Vietnam $6,180,101.20 
Zambia $31,945,622.57 
Zimbabwe $25,961,770.18 
Total $226,614,060.26 
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Table 3: Total Generic ARV Expenditures 
from PEPFAR-Supported Countries in FY 
2014 
Country ARV Expenditures 
Botswana $1,109,720.71 
Burkina Faso $280.00 
Burundi $355,857.97 
Cameroon $459,717.30 
Congo, DRC $1,602,386.02 
Côte d'Ivoire $12,512,816.03 
Ghana $2,348,550.74 
Guyana $105,519.58 
Haiti $12,766,271.17 
Mozambique $40,208,699.02 
Namibia $2,531,325.26 
Nigeria $54,552,209.40 
Rwanda $9,780,723.70 
Senegal $200.00 
South Africa $502,464.76 
South Sudan $811,416.93 
Swaziland $649,350.00 
Tanzania $1,322,314.13 
Togo $153,781.24 
Uganda $12,497,819.86 
Vietnam $7,537,796.65 
Zambia $27,087,851.26 
Zimbabwe $22,477,140.19 
Total $211,374,211.92  
 
 
 
 
 
 
Based on the SCMS Delivery History 
Dataset, PEPFAR-supported countries 
spent $186,574,684.69 on generic ARV 
drugs in FY 2012, $226,614,060.26 in FY 
2013, and $211,374,211.92 in FY 2014 as 
shown in Tables 1, 2 and 3. Nigeria spent 
$41,698,164.61 in FY 2012 and 
$54,552,209.40 in FY 2014 on generic 
ARVs, more than any other country 
program observed, respectively. Similarly, 
Mozambique spent the most funds on 
generics ($45,068,284.16) than the other 
observed countries in FY 2013. 
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Table 4: Total Name Brand ARV 
Expenditures from High Burden 
Countries in FY 2012 
Country ARV Expenditures 
Angola $14,793.60 
Congo, DRC $3,698.40 
Côte d'Ivoire $580,923.60 
Guyana $2,493.62 
Haiti $29,260.64 
Mozambique $1,150.80 
Rwanda $12,328.00 
South Africa $273,711.92 
Tanzania $22,806.80 
Uganda $444,287.29 
Vietnam $1,270,870.78 
Zambia $69,653.20 
Zimbabwe $496,276.32 
Total $3,222,254.97 
 
Table 5: Total Name Brand ARV 
Expenditures from High Burden 
Countries in FY 2013 
Country ARV Expenditures 
Congo, DRC $10,293.88 
Côte d'Ivoire $2,058,297.18 
Dominican 
Republic $148,250.80 
Guyana $66,329.92 
Haiti $71,271.50 
Mozambique $1,066,103.80 
Nigeria $2,314,167.56 
Rwanda $286,559.88 
South Africa $190,873.93 
Tanzania $1,482,592.34 
Uganda $1,394,936.06 
Vietnam $2,598,901.00 
Zambia $1,680,488.80 
Zimbabwe $77,341.50 
Total $13,446,408.15 
 
Table 6: Total Name Brand ARV 
Expenditures from High Burden 
Countries in FY 2014 
Country ARV Expenditures 
Burkina Faso $171.25 
Burundi $6,048.00 
Cameroon $6,660.00 
Côte d'Ivoire $53,780.90 
Guyana $23,107.44 
Haiti $554,634.70 
Mozambique $1,552,459.00 
Nigeria $3,245,867.70 
Rwanda $88,470.88 
Senegal $1,864.00 
South Africa $75,568.80 
Uganda $1,237,351.95 
Vietnam $2,851,679.00 
Zambia $279,290.84 
Zimbabwe $995,732.56 
Total $10,972,687.02 
 
From FY 2012 to FY 2014, these SCMS 
partners spent $3,222,254.97, 
$13,446,408.15, $10,972,687.02 on name-
brand ARVs respectively for a total of 
$27,641,350.14 over three years. In FY 
2012 and FY 2013, Vietnam spent more 
funds on name brand ARVs than the other 
countries observed ($1,270,870.78 and 
$2,598,901, respectively). Nigeria had the 
highest expenditures for FY 2014 with 
$3,245,867.70. 
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Table 7: Total Name Brand Purchase 
Orders from PEPFAR-Supported 
Countries in FY 2012 
Brand Name of 
ARV 
Number of 
Purchase Orders 
Aluvia 11 
Epivir 4 
Intelence 3 
Isentress 4 
Kaletra 28 
Norvir 13 
Prezista 4 
Videx 4 
Zerit 3 
Ziagen 4 
Total 78 
 
There were 78 name brand ARV 
transactions in FY 2012. The most 
frequently purchased name brand 
medication was Keletra with a total of 28 
purchases. 
 
 
 
 
 
 
 
 
 
Table 8: Total Name Brand Purchase 
Orders from PEPFAR-Supported 
Countries in FY 2013 
Brand Name of 
ARV 
Number of  
Purchase Orders 
Aluvia 49 
Crixivan 1 
Epivir 5 
Intelence 5 
Invirase 1 
Isentress 6 
Kaletra 37 
Norvir 17 
Prezista 8 
Reyataz 7 
Videx 4 
Viread 1 
Zerit 1 
Ziagen 2 
Total 144 
 
In FY 2013, there were 144 name brand 
ARV transactions. The most frequently 
purchased name brand medication was 
Aluvia with a total of 49 purchases. 
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Table 9: Total Name Brand Purchase 
Orders from PEPFAR-Supported 
Countries in FY 2014 
Brand Name 
of ARV 
Number of 
Purchase Orders 
Aluvia 29 
Epivir 1 
Intelence 17 
Invirase 7 
Isentress 26 
Kaletra 32 
Norvir 22 
Prezista 19 
Reyataz 10 
Stocrin/Sustiva 1 
Total 164 
There were 164 name brand ARV 
transactions in FY 2014. The most 
frequently purchased name brand 
medication was Keletra with a total of 32 
purchases. 
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Chapter V 
DISCUSSION 
There are a few implications to the WHO’s recent recommendations to increase ART 
to all HIV-affected individuals and the UNAIDS 90-90-90 goals. To meet these targets 
established by UNAIDS and WHO, it is necessary to increase the volume of ARVs to the 
affected countries and populations. The increase in ARVs would require a closer look at 
how countries spend their allocated funds on ARV procurement to supply the target 
populations adequately and efficiently. 
From 2012 to 2013, the procurement of overall and generic ARVs increased, 
however, from 2013 to 2014, there was a decrease in generic and overall ARV 
procurement. The number of brand name ARV transactions increased during this three 
year period from 78 in FY 2012, 144 in FY 2013, and 164 in FY 2014 respectively. The anti-
retroviral drug Keletra was the most frequently purchased ARV in FY 2012 and FY 2014. In 
FY 2013, the most frequently purchased ARV was Aluvia. 
 One obstacle in obtaining generic ARVs is slow registration processes in a few 
PEPFAR-funded countries (PEPFAR, 2009). Drugs that are distributed through the supply 
chain must be registered with the FDA through PEPFAR. Once they are FDA approved or 
even tentatively approved, drugs are then listed on the WHO website and/or submitted for 
the WHO Prequalification Programme (FDA, 2015). WHO Prequalification Programme 
ensure the quality of drugs and supplies for high burden diseases. This entire process can 
take months or years to complete. If there is an extensive delay, countries are forced to use 
the innovator drug, the product that was initially developed and typically sold at a higher 
price, instead of the generic that is under the registration process.  
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Another obstacle is the ARV tender process. Country governments often discuss the 
transactional processes and prices with the drug manufacturers far in advance to the 
implementation of services. In most cases, countries may agree to multi-year contracts with 
ARV drug manufacturers which reduce the flexibility in lowering ARV prices in the future 
(Holmes et al., 2010).  
 Producing ARVs locally, instead of importing, may also be considered. One study 
presented a case where two countries, Mozambique and Zimbabwe, implemented their 
own pharmaceutical manufacturing sectors (Russo & Banda, 2015). Another study from 
Tanzania found that locally produced drugs were found both in rural and urban areas, 
while imported medicine was mostly found in urban areas (Mujinja et al., 2014). This 
suggests that having local production may increase the availability of drugs in rural areas. 
However, it is worth noting that these initiatives faced obstacles, such as human resources 
deficiencies and unfavorable business environments (Russo & Banda, 2015). The current 
challenge for these companies is ensuring the costs of production remain low in order to 
compete with international manufacturers. 
Although there are barriers to obtaining generic formulations for anti-retrovirals, 
there is a dire consequence of low uptake of ARVs. If a high burden country is unable to 
sustain or secure enough ARVs for HIV-affected individuals, it is unlikely that HIV/AIDS will 
be eliminated in that location within the next several years, according to the WHO 
recommendations.  
 
 
 
13 
 
Chapter VI 
CONCLUSION 
It is also recommended that the international public health community continues to 
explore solutions to overcome obstacles that prevent countries from securing generic 
ARVs. Policy officials may consider revising the ARV registration process to decrease the 
time between the initial drug submission, drug approval and drug distribution to the 
country. High burden country governments may consider establishing shorter contracts 
and negotiating the ARV tender processes annually, instead of every few years in order to 
make adjustments to cheaper ARVs as needed. Countries may also invest in producing their 
ARVs locally. In the implementation phase, this may require the support of non-profit or 
international organizations to develop an efficient production system, but this effort may 
have the potential to increase the number of ARVs in rural and urban regions over time.  
As the quantity of treatment supplies increases, it will be necessary for international 
partners to consider the burden on the countries and regions who may not have the 
capacity for this unprecedented scale-up (Jamieson & Kellerman, 2016). It will also be 
necessary to adjust the storage space, tracking methods and human resources to meet 
these needs over time.  
Integrating planning methods between the global supply chain managers, 
partnering organizations and policy makers will be critical in achieving such ambitious 
goals, such as the UNAIDS 90-90-90 targets and WHO recommendations. As researchers, 
health staff and policy officials continue to work together to reduce the prevalence of HIV, 
eventually the global community will be able to overcome this epidemic. 
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Chapter VII 
LIMITATIONS 
Only SCMS data were considered, therefore the findings of this study cannot be 
generalized and may only be applied to countries who receive support from SCMS and 
PEPFAR. Also, the cost of shipping and international taxes were not considered in the total 
expenditure calculation. Other costs associated with HIV treatment and supplies were not 
applied to the final calculations. Lastly, the SCMS Delivery History Dataset lists the ARV 
delivery date but does not label the fiscal year in which the funds originated. Therefore, it is 
worth noting that the SCMS ARV expenditures indicated by fiscal year are estimates.   
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